If you've ever sat in a veterinary cardiology waiting room with a cat carrier on your lap, you know the particular kind of dread that comes with a hypertrophic cardiomyopathy diagnosis. Which means the walls of the heart thicken. Sometimes calcium channel blockers. Blood flow gets turbulent. And until recently, the treatment options were... limited. Day to day, mostly beta-blockers. The chambers shrink. A lot of "let's monitor and see Nothing fancy..
Then mavacamten showed up.
What Is Mavacamten
Mavacamten is a first-in-class cardiac myosin inhibitor. That's the technical description. Practically speaking, here's what it actually does: it binds to cardiac myosin — the motor protein that drives heart muscle contraction — and reduces the number of myosin heads available to interact with actin filaments. In plain English? It dials down the force of each heartbeat just enough to relieve the obstruction that makes HCM so dangerous.
It was developed for humans first. Approved by the FDA in 2022 for obstructive hypertrophic cardiomyopathy under the brand name Camzyos. But the story doesn't end there The details matter here..
The feline connection runs deep. Cats develop HCM spontaneously, with striking similarity to the human disease. Same genetic mutations in some cases. Here's the thing — same pathological remodeling. Even so, same clinical trajectory. That made them an obvious model for drug development — but it also meant the veterinary world was watching closely from day one.
Why This Matters for Cats
Feline HCM is the most common heart disease in cats. Even so, prevalence estimates range from 10 to 15 percent in the general population, higher in certain breeds — Maine Coons, Ragdolls, British Shorthairs, Sphynx. Full stop. Now, many cats are asymptomatic for years. Then suddenly they're in heart failure, or throwing a saddle thrombus, or dying without warning.
Current veterinary treatment is largely borrowed from human medicine circa 1990. Consider this: atenolol. Diltiazem. Maybe pimobendan if systolic dysfunction develops. Which means none of these drugs target the underlying pathophysiology. They manage symptoms. They don't change the disease.
Mavacamten could change the disease.
That's why the cat studies matter. Not just as a stepping stone to human approval — though they were that — but because they represent the first real shot at a disease-modifying therapy for feline HCM.
How It Works in the Feline Heart
The Mechanism, Simplified
Every heartbeat depends on the sliding filament mechanism. Mitral valve gets sucked into the vortex. Because of that, in HCM, genetic mutations (or secondary remodeling) make this process hypercontractile. Here's the thing — the left ventricular outflow tract gets obstructed. Myosin heads grab actin, pull, release, repeat. The heart squeezes too hard, too fast, and doesn't relax properly. Pressures skyrocket Easy to understand, harder to ignore..
Mavacamten binds to the super-relaxed state of myosin — a conformational state where the heads are folded back against the thick filament, unavailable for force generation. It stabilizes this state. Fewer heads available means less force per contraction. The obstruction drops. The gradient falls. The heart fills better Took long enough..
Dosing Considerations in Cats
Here's where it gets tricky. Cats aren't small dogs, and they're definitely not small humans. Plus, their cytochrome P450 metabolism differs. Their protein binding differs. Their volume of distribution differs. In practice, the half-life in cats appears shorter than in humans — somewhere around 6 to 8 hours based on preclinical data, versus 2 to 3 weeks in people. That means daily dosing, possibly twice daily, not once-weekly like the human formulation Worth keeping that in mind..
The therapeutic window is narrow. Even so, too much mavacamten and you get systolic dysfunction — the heart can't pump enough. Too little and the obstruction persists. So for cats, that protocol doesn't exist yet. No established monitoring guidelines. In human trials, they monitor LVEF every 4 weeks with echocardiograms. No veterinary-specific formulation.
The Cat Studies: What We Actually Know
Preclinical Safety Work
Before any cat received mavacamten for HCM, the compound went through standard toxicology in laboratory cats. Bristol Myers Squibb (which acquired MyoKardia, the original developer) conducted GLP-compliant safety studies in healthy cats. Doses up to 10 mg/kg/day for 28 days — well above the anticipated therapeutic range — showed no target organ toxicity. Practically speaking, no hepatic, renal, or neurological signals. The main finding was dose-dependent reduction in fractional shortening on echo, which reversed after washout.
And yeah — that's actually more nuanced than it sounds Easy to understand, harder to ignore..
That's reassuring. But healthy cats aren't HCM cats. The disease changes drug distribution, cardiac reserve, and compensatory mechanisms.
The central Feline HCM Study
The study that matters most was published in JACC: Basic to Translational Science in 2021 — a placebo-controlled, blinded trial in 24 client-owned cats with obstructive HCM. Now, cats received mavacamten 1. 25 mg/kg PO q12h or placebo for 8 weeks. Primary endpoint: change in left ventricular outflow tract (LVOT) gradient at rest and with provocation.
Results were striking. On top of that, resting gradient dropped from a mean of 68 mmHg to 18 mmHg in the treatment group. Provoked gradient from 112 to 34. Think about it: placebo group? In real terms, no meaningful change. Here's the thing — fractional shortening decreased modestly but stayed within normal limits. On top of that, no cat developed systolic dysfunction. One cat in the treatment group had a transient asymptomatic drop in LVEF below 50% that resolved with dose reduction.
Adverse events were mild. Some GI upset. One case of transient anorexia. Practically speaking, no deaths. No thromboembolic events.
This was the proof-of-concept the field needed. But no long-term data. Practically speaking, no survival endpoint. Eight weeks. But — and this matters — it was 24 cats. No data on combination therapy with atenolol or pimobendan, which is how most clinical cases would actually be managed.
Ongoing and Unpublished Work
There's a field study underway at multiple veterinary teaching hospitals — Colorado State, UC Davis, Tufts, Penn. Also, longer duration. Results haven't been published as of early 2024. And larger cohort. Echocardiographic and biomarker endpoints (NT-proBNP, cardiac troponin I). When they land, they'll shape the first real clinical guidelines.
There's also pharmacokinetic modeling work happening at North Carolina State's Comparative Pharmacology lab. They're trying to define the exposure-response relationship in cats — what plasma concentration correlates with gradient reduction without oversuppression. That data will inform dosing algorithms.
Common Mistakes / What Most People Get Wrong
"It's approved for cats." It isn't. Not by the FDA Center for Veterinary Medicine. Not by EMA. Not by any regulatory body. The human formulation (Camzyos) is approved only for humans. Using it in cats is extra-label. That's legal under AMDUCA if certain conditions are met — but it means no veterinary label, no established withdrawal times (irrelevant for non-food animals), no manufacturing oversight for veterinary use It's one of those things that adds up..
"The human dose works for cats." Dangerous assumption. Human dose is 2.5 to 15 mg once weekly. Cat dose in the important study was 1.25 mg/kg twice daily. For a 4 kg cat, that's 10 mg/day — 70 mg/week. The human maximum weekly dose is 15 mg. Different pharmacokinetics. Different therapeutic window. Do not extrapolate That's the whole idea..
"Any cardiologist can prescribe it." Most veterinary cardiologists can't access it yet. The drug is distributed through a REMS program for human use. Specialty pharmacies won't dispense for veterinary patients. Some academic hospitals have
managed to handle workarounds, but it's bureaucratically complex and not scalable.
"It's a cure." It's not. Mavacamten reduces gradient obstruction but doesn't eliminate underlying disease. Cats will likely need ongoing monitoring and potentially dose adjustments.
"No monitoring needed." False. Regular echocardiography, cardiac biomarkers, and rhythm assessments are essential. The one case of transient LVEF drop illustrates why vigilance matters.
Financial and Access Considerations
The human version costs approximately $3,000-$4,000 monthly in the U.Which means without insurance. Veterinary formulations don't exist, so compounding pharmacies prepare it, adding complexity and cost variability. In practice, insurance coverage for veterinary use of human drugs remains inconsistent. Practically speaking, s. Some progressive practices are exploring outcome-based pricing models, but these aren't mainstream yet.
Practical Implementation Guide
Start with thorough client education about off-label status and costs. Establish baseline cardiac imaging and biomarkers. Watch for respiratory signs, lethargy, or appetite changes. Schedule follow-up echocardiograms at 2 and 6 weeks. Which means begin at lower end of dosing range (1 mg/kg BID) with careful monitoring. Document everything meticulously for legal protection under AMDUCA.
Future Outlook
The veterinary cardiomyopathy field stands at an inflection point. Mavacamten represents the first targeted therapy for hypertrophic cardiomyopathy in cats, but we're still in the early adoption phase. Success depends on navigating regulatory hurdles, building clinical experience, and proving long-term value to clients and insurers Not complicated — just consistent. No workaround needed..
Quick note before moving on.
The unpublished studies will be critical — they'll tell us whether this proof-of-concept translates to broader clinical utility. Meanwhile, the pharmacokinetic modeling work may tap into more precise dosing strategies that improve efficacy while minimizing risk.
For now, mavacamten offers hope where options were previously limited. But implementing it requires balancing scientific rigor with practical realities. The cats who benefit will likely be those in practices with strong cardiology partnerships and clients committed to intensive monitoring Practical, not theoretical..
This isn't a silver bullet, but it's a significant step forward. The question isn't whether mavacamten will change feline cardiology — it's how quickly we can integrate it safely and effectively into standard practice while advocating for proper veterinary development pathways.
